Sara M. Haserlat
Harvard University · 22 works · 12,649 citations · h-index 10
Top works
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials
- Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation ofERBB2rather thanEGFR
- Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas
- Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts
- Frequent Met Oncogene Amplification in a Brca1/Trp53 Mouse Model of Mammary Tumorigenesis
- Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias
- CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma
- Prevalence and Functional Analysis of Sequence Variants in the ATR Checkpoint Mediator Claspin
- Abstract 4972: Preclinical development of a first-in-class NKp30xBCMA NK cell engager for the treatment of multiple myeloma
- Abstract 3239: CTX-5861 mediated SIRPα blockade combines with tumor targeting antibodies, checkpoint blockade and/or CD137 agonism to elicit curative anti-tumor activity in syngeneic mouse models
- Abstract 4972: Preclinical development of a first-in-class NKp30xBCMA NK cell engager for the treatment of multiple myeloma
- Supplementary Data from Prevalence and Functional Analysis of Sequence Variants in the ATR Checkpoint Mediator Claspin
- Supplementary Data from Prevalence and Functional Analysis of Sequence Variants in the ATR Checkpoint Mediator Claspin
- Abstract 3239: CTX-5861 mediated SIRPα blockade combines with tumor targeting antibodies, checkpoint blockade and/or CD137 agonism to elicit curative anti-tumor activity in syngeneic mouse models
- Abstract 4586: Essential role of fibroblast growth factor receptor 2 (FGFR2) in tumorigenesis of human cancers with activated FGFR2 signaling demonstrated by functional blocking antibodies
- Data from Frequent Met Oncogene Amplification in a Brca1/Trp53 Mouse Model of Mammary Tumorigenesis
- Supplementary Methods and Table from Frequent Met Oncogene Amplification in a Brca1/Trp53 Mouse Model of Mammary Tumorigenesis
- Data from Prevalence and Functional Analysis of Sequence Variants in the ATR Checkpoint Mediator Claspin
- Data from Frequent Met Oncogene Amplification in a Brca1/Trp53 Mouse Model of Mammary Tumorigenesis